Earnings summaries and quarterly performance for Xtant Medical Holdings.
Executive leadership at Xtant Medical Holdings.
Board of directors at Xtant Medical Holdings.
Research analysts who have asked questions during Xtant Medical Holdings earnings calls.
Chase Knickerbocker
Craig-Hallum Capital Group
3 questions for XTNT
Also covers: AVDL, BFLY, BVS +17 more
Ryan Zimmerman
BTIG
2 questions for XTNT
Also covers: ALC, GEHC, GKOS +23 more
A[
Akar [Unknown Last Name]
Not mentioned
1 question for XTNT
I[
Izzy [on for Ryan]
Not mentioned
1 question for XTNT
J[
Jake [on for Chase Knickerbocker]
Craig-Hallum
1 question for XTNT
Recent press releases and 8-K filings for XTNT.
Xtant Medical Completes Sale of Coflex Assets and Paradigm OUS Businesses
XTNT
M&A
New Projects/Investments
- Xtant Medical Holdings, Inc. completed the sale of certain non-core Coflex® spinal implant assets and all OUS entities of Paradigm Spine GmbH to Companion Spine, LLC, and its affiliates on December 1, 2025.
- The transaction's purchase price was approximately $19.2 million, consisting of $11.0 million in cash and $8.2 million in short-term seller financing in the form of an unsecured promissory note.
- Xtant intends to use the net proceeds from the sale to reduce long-term debt and provide additional cash liquidity.
- This sale allows Xtant to enhance its focus on its core biologics business and is expected to enable the company to operate without the need for additional external capital.
Dec 1, 2025, 9:05 PM
Xtant Medical Reports Strong Third Quarter 2025 Financial Results and Reiterates Full-Year Guidance
XTNT
Earnings
Guidance Update
M&A
- Xtant Medical reported Q3 2025 total revenue of $33.3 million, a 19% increase year-over-year, and generated $4.6 million in cash from operations.
- The company achieved net income of $1.3 million and Adjusted EBITDA of $4.5 million for Q3 2025, significantly improving from losses in the prior year quarter.
- Xtant Medical reiterated its full-year 2025 revenue guidance of $131-$135 million, projecting 11%-15% growth over FY24.
- The company anticipates the sale of certain non-core hardware assets and OUS businesses to Companion Spine to close by year-end 2025.
Nov 10, 2025, 9:46 PM
Xtant Medical Reports Q3 2025 Financial Results
XTNT
Earnings
Guidance Update
M&A
- Xtant Medical Holdings reported revenue of $33.3 million for the third quarter ended September 30, 2025, marking a 19% increase compared to the prior year quarter.
- The company achieved a net income of $1.3 million and Adjusted EBITDA of $4.5 million in Q3 2025, a significant improvement from a net loss of $5.0 million and an Adjusted EBITDA loss of $1.0 million in the prior year quarter, respectively.
- Cash generated from operations for Q3 2025 was $4.6 million, contrasting with cash used in operations of $1.7 million in the prior year quarter.
- Xtant Medical reiterated its full-year 2025 revenue guidance to $131-$135 million, which represents 11%-15% growth over FY24 revenue.
- The previously announced sale of certain hardware assets and OUS businesses to Companion Spine is anticipated to close by year-end 2025, and the company also launched CollagenX™.
Nov 10, 2025, 9:28 PM
Quarterly earnings call transcripts for Xtant Medical Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more